tiprankstipranks
Trending News
More News >
Positive Outlook for COMPASS Pathways: Strong Clinical Progress and Financial Stability Support Buy Rating
PremiumRatingsPositive Outlook for COMPASS Pathways: Strong Clinical Progress and Financial Stability Support Buy Rating
11d ago
Psychedelic: Compass, GH Research, MindMed report quarterly earnings
Premium
The Fly
Psychedelic: Compass, GH Research, MindMed report quarterly earnings
11d ago
Compass Pathways reports Q1 EPS (24c), consensus (49c)
Premium
The Fly
Compass Pathways reports Q1 EPS (24c), consensus (49c)
11d ago
Psychedelic: Exclusive talk with retreat provider ONE Retreats
PremiumThe FlyPsychedelic: Exclusive talk with retreat provider ONE Retreats
2M ago
Psychedelic: Exclusive talk with biotech company Clearmind Medicine
Premium
The Fly
Psychedelic: Exclusive talk with biotech company Clearmind Medicine
2M ago
Psychedelic: atai Life Sciences, NRx report quarterly results
Premium
The Fly
Psychedelic: atai Life Sciences, NRx report quarterly results
2M ago
Optimistic Buy Rating for COMPASS Pathways: Strategic Trials and Strong Financial Position Bolster Confidence in COMP360’s Potential
PremiumRatingsOptimistic Buy Rating for COMPASS Pathways: Strategic Trials and Strong Financial Position Bolster Confidence in COMP360’s Potential
3M ago
Buy Rating for COMPASS Pathways: Promising Phase 3 Trial Progress and Strong Financial Position
Premium
Ratings
Buy Rating for COMPASS Pathways: Promising Phase 3 Trial Progress and Strong Financial Position
3M ago
Compass Pathways price target lowered to $15 from $23 at Canaccord
Premium
The Fly
Compass Pathways price target lowered to $15 from $23 at Canaccord
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100